Should you buy, sell or hold Cipla, Fortis Healthcare, Bharti Airtel, BPCL, ONGC shares today?
Brokerages are bullish on celebrity investor Rekha Jhunjhunwala-owned Fortis Healthcare citing the company's good growth outlook. They are divided on telecom stocks such as Bharti Airtel and Indus Towers, and skeptical on energy company stocks such as BPCL and ONGC.
Brokerages are upbeat on Cipla despite the pharma company receiving eight observations from US drug regulator FDA for its Pithampur facility in Madhya Pradesh. They are bullish on Rekha Jhunjhunwala-owned Fortis Healthcare citing the company's good growth outlook, and divided on telecom stocks, such as Bharti Airtel and Indus Towers.
Here's what top brokerages make of some of the key stocks in focus today:
JPMorgan and Macquarie are upbeat on Cipla. According to the brokerage, the Pitampura unit is one of the company’s key manufacturing facilities besides Goa and the Invagen plant in the US.
Shark Tank India Season 3: From Nvidia, HP jobs to establishing startup to kill mosquitoes; how Eco BioTraps founder turns heads
PM Modi to lay foundation stone, dedicate to nation redevelopment of 554 stations on Feb 26: Divisional Railway Manager
BITS Mumbai Campus Inauguration: "India on the way to become the third largest economy," says Kumar Mangalam Birla
Exclusive: Finance Ministry asks ONGC, OIL to fund India’s hydrocarbon hunt; promises to reimburse losses
Macquarie points out that Cipla manufactures respiratory products like Proventil Brovana and Pulmicort at the Pithampur plant.
Samvardhana Motherson shares
Jefferies maintains a ‘hold’ rating on Samvardhana Motherson with a target price of Rs 70 per share, as the company’s subsidiary acquires a 100 per cent stake in Germany's SAS Autosystemtechnik, a global provider of cockpit module assembly and logistics services to auto original equipment manufacturers (OEMs).
According to the brokerage, the acquisition will add 10-15 per cent to Motherson’s revenue and EBITDA.
Goldman Sachs maintains ‘buy’ on Bharti Airtel and ‘neutral’ on Indus Towers. The brokerage reduces its target price for Bharti Airtel to Rs 870 apiece from Rs 875. It recuced the target for Indus Towers to Rs 200 apiece from Rs 230 per share.
Morgan Stanley maintains an ‘overweight’ stance on Shriram Finance with a target price of Rs 1,580 per share citing the company's strong Q3 earnings and fundamentals.
According to the brokerage, the valuation discount to historical mean and to peers has widened. Morgan Stanley expects the stock to rally after supply overhangs.
Nomura maintains a ‘buy’ call on Fortis Healthcare with a target price of Rs 325 per share as against Rs 319 apiece earlier. The brokerage is positive on traction in the company's hospital business with scope for further improvement, and its investments toward technology upgrades.